Sonus ends EchoGen agreement with Daiichi
This article was originally published in Clinica
Executive Summary
Sonus has ended its licensing agreement with Daiichi Pharmaceutical for EchoGen, its ultrasound contrast agent, owing to concern over a lack of progress in clinical trials in Japan. Sonus claims, that after completing the first clinical trial in December 1997, "there has been no additional clinical work on EchoGen in Japan".